BOTANIX PHARMACEUTICALS LTD — Board/Management Information 2022

Mar 21, 2022

==> picture [114 x 50] intentionally omitted <==

22 March 2022

Danny Sharp appointed Non-Executive Director to Botanix Board

Philadelphia PA and Perth Australia, 22 March 2022 : Clinical dermatology company, Botanix Pharmaceuticals Limited (ASX: BOT, “Botanix” or “the Company”), is pleased to announce the appointment of global capital markets leader, Mr Daniel Sharp, to the Botanix Board of Directors as a Non-Executive Director.

Mr Sharp is an investment banker with more than 30 years’ experience in capital markets globally, advising the boards of technology and healthcare-based organisations. He also has a significant network of institutional and private wealth investors globally. Mr Sharp is an immediate past Corporate Finance Executive Director of Canaccord Genuity and has previously spearheaded the Corporate Finance departments at both Shaw and Partners and Lodge Partners.

He is currently a Non-Executive Director of health informatics company Alcidion Group Ltd (ASX: ALC) and on the Investment Committee of the Baker Heart and Diabetes Institute. He holds a Bachelor of Economics and Law and is a CFA Charter Holder.

Botanix President and Executive Chair Vince Ippolito said : “We are excited to welcome Danny to the Board of Botanix and the Company is very excited to gain the benefit of Danny’s extensive capital market and Board advisory experience.

Danny’s appointment comes at an important time for Botanix as we move into the next phase of our maturity with an advancing drug commercialisation portfolio and broadening strategic opportunities. His strong commercial experience combined with knowledge of global investment markets, will be highly beneficial in both the short and longer term in driving shareholder value.”

The Company has agreed that in addition to directors fees, it will issue Mr Sharp options under its Employee Securities Incentive Plan as follows: 1,000,000 options with an exercise price to be the lower of the closing share price on the previous days’ trading before issue and the 7 day VWAP of the shares traded before the day of issue expiring one year after the date of issue; and 4,000,000 options with an exercise price at a 33% premium to the lower of the closing share price on the previous day’s trading before the date of issue and the 7-day VWAP of the shares traded before the date of issue, expiring three years after the issue date, vesting progressively over three years. Shareholder approval will not be sought for the issue of options (or their exercise) as Mr Sharp was not a director of Botanix at the time of the negotiations and had no influence over the decision to issue the options.

Release authorised by

Vince Ippolito President and Executive Chairman

==> picture [113 x 50] intentionally omitted <==

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology focused company based in Philadelphia and Phoenix (USA) committed to the development of pharmaceutical products that are underpinned by science and supported by well-controlled randomised clinical trials. The Company has two separate development platforms - dermatology and antimicrobial products. Botanix has an exclusive license to use a proprietary drug delivery system (Permetrex[TM] ) for direct skin delivery of active pharmaceuticals in all skin diseases, which it utilises in its existing development programs and is being explored with a view to being utilized in a number of other product opportunities. To learn more please visit: http://www.botanixpharma.com/

For more information, please contact:

General enquiries Investor enquiries Media enquiries Corporate Communications Hannah Howlett Haley Chartres Botanix Pharmaceuticals WE Communications H^CK P: +61 8 6555 2945 P: +61 450 648 064 P: +61 423 139 163 investors@botanixpharma.com hhowlett@we-worldwide.com haley@hck.digital

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the Company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” ”potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company’s ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company’s ability to obtain marketing approvals for is product candidates. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.